The global blood screening market is expected to reach USD 6.62 billion by 2030, registering a CAGR of 11.7% from 2023 to 2030, according to a new report by Grand View Research, Inc. The growth of the market is attributed to the increase in screening of donor and continuous technological advancement by the market players. Demand for blood screening tests is increasing continuously due to increasing donation, rising awareness about transfusion-transmitted diseases, and technological developments in the industry. Furthermore, governments of various countries are in process to mandates testing all donated blood for several viruses.
Thorough screening is necessary for all donated blood to ensure that recipients receive the safest products. As of 2015, such testing consists of screening for red cell antibodies, and the infectious diseases agents: HIV-1, HIV-2, hepatitis virus, West Nile Virus (WNV), Human T-Lymphotropic Virus (HTLV) T. Cruzi, and T. pallidum (syphilis). The result of all these assays must be negative for blood donation.
Technological developments increase the sensitivity and efficiency of the tests. For instance, in 2016, the U.S. FDA approved the Procleix Zika virus assay from Hologic, Inc. and Grifols to screen donated blood. Furthermore, the U.S. FDA approved next-generation sequencing (NGS) technology in 2013. The technology is cheaper and faster than previous DNA analysis methods.
Request a free sample copy or view report summary: Blood Screening Market Report
The reagent segment accounted for the largest revenue share of around 73.0% in 2022 and is expected to grow at the fastest CAGR of 12.0% over the forecast period.
North America dominated the market and accounted for the largest revenue share of 39.0% in 2022 owing to the presence of key industry players, increased adoption of the blood screening process, stringent FDA regulations for transfusion, rising infectious disease prevalence, and greater patient affordability are responsible for maintaining its position during the forecast period.
Asia Pacific is expected to grow at the fastest CAGR of 13.5% over the forecast period owing to increasing awareness about blood donation, rising patient affordability, and the focus of key industry players on emerging countries in the region.
Grand View Research has segmented the blood screening market by product, technology, and region:
Blood Screening Technology Outlook (Revenue, USD Million, 2018 - 2030)
Nucleic Acid Amplification Test (NAT)
ELISA
Chemiluminescence Immunoassay (CLIA) and Enzyme Immunoassay (EIA)
Next Generation Sequencing
Western Blotting
Blood Screening Product Outlook (Revenue, USD Million, 2018 - 2030)
Reagent
Instrument
Blood Screening Regional Outlook (Revenue, USD Million, 2018 - 2030)
North America
U.S.
Canada
Europe
UK
Germany
France
Italy
Spain
Sweden
Norway
Denmark
Asia Pacific
Japan
China
India
Australia
Thailand
South Korea
Latin America
Brazil
Mexico
Argentina
Middle East and Africa
Saudi Arabia
South Africa
UAE
Kuwait
List Of Key Players in the Blood Screening Market
Abbott
Danaher Corporation (Beckman Coulter)
Becton Dickinson and Company
Bio-Rad Laboratories, Inc.
Hoffman-La Roche Ltd.
Grifols, S.A.
Ortho-Clinical Diagnostics, Inc.
Siemens Healthcare GmbH
Thermo Fisher Scientific, Inc.
SOFINA s.a (Biomerieux)
"The quality of research they have done for us has been excellent..."